September 04, 2008

Similar documents
TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING

Your single-source laboratory solution. FISH Probe Library

Outline. Chromosomal analysis FISH. Chromosomal abnormalities in cancer. Clinical application of cytogenetics. Procedure Nomenclature

scfish: A Primer Peter K. Rogan, Ph.D. Joan H. M. Knoll, Ph.D., FACMG, FCCMG Children s Mercy Hospitals and Clinics Tuesday, July 29, 2003

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Clinical Cytogenomics Laboratory. Laboratory. Leading diagnostics for better medicine. Beaumont

HEMATOPATHOLOGY SERVICES

CYTOGENETICS Dr. Mary Ann Perle

New and Developing Technologies for Genetic Diagnostics National Genetics Reference Laboratory (Wessex) Salisbury, UK - July 2010 BACs on Beads

Role of FISH in Hematological Cancers

Lab Guide 2018 Diagnostic Genomic Division(DGD)

Hematology Diagnostic Services

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Oncology Cytogenetics Diagnostic Service - User Guide 2014

Karyology. Preparation and study of karyotypes is part of Cytogenetics.

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Recommended Timing for Transplant Consultation

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)

Clinical Cytogenetic Services

Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach

Molecular Diagnosis. Nucleic acid based testing in Oncology

PhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA

CLL Complete SM Report

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

CMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

molecular oncology services

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

Introduction to Cytogenetics

Chapter 2 Classical and Molecular Cytogenetic Analysis of Hematolymphoid Disorders

HEMATOLOGIC MALIGNANCIES BIOLOGY

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

DNA-FISH Probe Catalog Empowering Personalized Cancer Treatment.

Microdeletion and Prenatal FISH Probes

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

Myelodysplastic Syndrome Case 158

Acute Lymphoblastic and Myeloid Leukemia

TARGETED THERAPY FOR CHILDHOOD CANCERS

Case 1B. 46,XY,-14,+t(14;21)

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Cytogenetics Update. Lynda J Campbell

Chromosomal Abnormalities and Karyotypes Creating a Karyotype

The Power of Observation

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

ACMG/CAP Cytogenetics CY

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Chromosomal Aberrations

Genetic Testing Oncology

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

Immunopathology of Lymphoma

NeoTYPE Cancer Profiles

Information for you about Panorama s Microdeletion Screening BROUGHT TO YOU BY:

Treatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Molecular Hematopathology Leukemias I. January 14, 2005

Understanding the Human Karyotype Colleen Jackson Cook, Ph.D.

Cytogenetic and Molecular Evaluation in Myelodysplastic Syndrome and in Acute and Chronic Leukemia

Diagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED

BHS training course. Laboratory Hematology Cytogenetics. Lucienne Michaux. Centrum voor Menselijke Erfelijkheid, UZLeuven

2013 AAIM Pathology Workshop

Collected: , PM Sent: , PM Received: , PM Preliminary: , PM. Notification Status: COMPREHENSIVE DIAGNOSIS

Adult Acute leukemia. Matthew Seftel. August

Introducing Western Diagnostic s Genomic Pathology

The spectrum of flow cytometry of the bone marrow

Diagnostic Molecular Pathology of Lymphoid Neoplasms

An Overview of Cytogenetics. Bridget Herschap, M.D. 9/23/2013

HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry

Myeloproliferative Disorders - D Savage - 9 Jan 2002

JAK2 V617F analysis. Indication: monitoring of therapy

Mixed Phenotype Acute Leukemias

A Presentation to: ABA. Howard M. Sandler, M.D. Sandler Occupational Medicine Associates, Inc. April 2008

MOC MGP General Molecular Genetics I (Mandatory 75-Question Module) analytical measurement range; CLSI MM06-A2 PCR assay performance and validation

HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor

XCyting DNA FISH Probes

Variations in Chromosome Structure & Function. Ch. 8

Leukocytosis - Some Learning Points

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Hematologic Malignancies. Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine

Increasing the Sensitivity of Genomic Assays Permits a Higher Resolution Study of the Human Genome. Our Current Knowledge of Genetics and Genomics

ROLE OF TUMOR MARKERS AND RECENT ADVANCES IN CANCER DIAGNOSIS

KHMDC Oncology Cytogenetics User Guide

Transcription:

27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com Test Updates September 04, 2008 Dear Valued Client: As you may be aware, in recent years there has been a tremendous challenge in our industry to retain trained cytogenetic staff to meet with the testing demand in this growing specialty. Your facility may have experienced delays in turnaround time, in part due to fluctuating staff levels at Specialty or other laboratories. While Specialty has been fortunate in recent months to have full staffing, we have determined that a new approach to our cytogenetic test offering will ensure a more stable and reliable delivery of test performance. Effective November 4, 2008, Specialty will combine its resources with those of our two closest affiliated laboratories. This aggregation will mean that staff from three laboratories will coalesce to provide an enhanced service level. Additional staffing will join our Valencia facility to provide the diagnostic portion of the testing process and the preanalytical procedures will be performed in the San Juan Capistrano facility. We believe this merger of resources will provide you with quality testing, uninterrupted service levels and better turn around time. In order to facilitate these changes, we will need to create new test codes for our offerings. Please see the listing below for current offerings and the replacement codes that will be in effect. If you currently order these tests, please make the appropriate changes to your Laboratory Information Systems. Thank you for choosing Specialty and we look forward to your continued support. For additional information, please visit our Web site at www.specialtylabs.com or contact Client Relations at 800-421-4449. Christopher Lockhart, M.D. Laboratory Director 1 of 5

Affected Tests: Effective November 4, 2008: 5880 Acute Lymphoblastic Leukemia by FISH Replacement: S51716 - FISH, ALL, Pre-B Panel 5874 Acute Myeloid Leukemia/High Grade Myelodysplasia by FISH Replacement: S51714 FISH, MDS/Myeloid Panel, -5/5q-, -7/7q-, +8,20q 5840 Acute Promyelocytic Leukemia t(15;17) [FISH] Replacement: S51693 - FISH, AML M3, PML/RARA, Translocation 15,17 12992 Amniocyte Culture Replacement: S51683 - Cell Culture for Possible Additional Prenatal Studies 5834 bcr/abl1 Gene Rearrangement (Philadelphia Chromosome) [FISH] Replacement: S51686 - FISH, CML/ALL, bcr/abl Translocation 9,22 5868 Burkitt Lymphoma t(8;14) by FISH Replacement: S51710 FISH, Burkitts/NHL/ALL, IGH/MYC, t(8;14) 5822 Chromosome Analysis Amniotic Fluid Replacement: S51687 - Chromosome Analysis, Amniotic Fluid 5818 Chromosome Analysis: Products of Conception/Skin Biopsies Replacement: S51688 - Chromosome Analysis, Tissue 5860 Chronic Lymphocytic Leukemia (CLL) by FISH Replacement: S51705 FISH, B-Cell Chronic Lymphocytic Leukemia (B-CLL) Panel 5862 Chronic Myelogenous Leukemia (CML) by FISH Replacement: S51686 - FISH, CML/ALL, bcr/abl Translocation 9,22 5852 Cytogenetics inv(16) [FISH] Replacement: S51685 FISH, AML, CBFB/MYH11, Inversion 16 5854 Cytogenetics MLL(11q23) [FISH] Replacement: S51715 FISH, MLL (11q23) Gene Rearrangement 5850 Cytogenetics t(8;21) [FISH] Replacement: S51682 FISH, AML, AML1/ETO Translocation 8,21 5814 Cytogenetics Congenital Disorders Replacement: S51689 Chromosome Analysis, Blood 5800 Cytogenetics Hematologic & Neoplastic Disorders Replacement: S51690 Chromosome Analysis, Hematologic Malignancy 5825 Cytogenetics Solid Tumors Replacement: S51691 Chromosome Analysis, Solid Tumor 2 of 5

5884 del(4)(q12) by FISH (FIP1L1-PDGFRA) 12990 Fibroblast Culture Replacement: S51683 Cell Culture for Possible Additional Prenatal Studies 5843 FISH Subtelomere Abnormalities [Totelvysion] Replacement: S51684 FISH, Subtelomere Screen 5892 FISH ALK 2p23 Replacement: S51706 FISH, ALCL, ALK, 2p23 Rearrangements 5894 FISH BCL6 3q27 5890 FISH C-MYC 8q24 Replacement: S51704 FISH, ALL/NHL, MYC-BA, 8q24 Rearrangement 5898 FISH Chromosome 1 Aneuploidy 5858 FISH Chromosome 18 Aneuploidy 5856 FISH Chromosome 7 Aneuploidy 5896 FISH del(13)(q14.3)d13s25 5869 FISH-20q12 D20S108 Replacement: S51681 FISH, Chromosome 20q Deletion 5863 FISH-IGH 14q32 Replacement: S51709 FISH, B-Cell Malignancy, IGH, 14q32 Rearrangement 5865 FISH-MALT1 18q21 Replacement: S51717 FISH, MALT Lymphoma, MALT1, 18q21 Rearrangement 5861 FISH-p53 17p13.1 5867 FISH-RB1 13q14 5885 FISH-Trisomy 13, 18, 21, X & Y [Aneuvysion] (Prenatal) Replacement: S51692 FISH, Prenatal Screen 3 of 5

5887 FISH-Trisomy 21 5872 Follicular Lymphoma t(14;18) by FISH Replacement: S51708 FISH, Follicular Lymphoma, IGH/BCL2, t(14;18) 5830 Genetic Diseases [FISH] Replacements: S51697 FISH, Angelman S51698 FISH, Cri du chat S51699 FISH, DiGeorge, Velocardiofacial (VCFS) S51700 FISH, Miller-Dieker S51701 FISH, Smith-Magenis S51702 FISH, Wolf-Hirschhorn S51720 FISH, SRY/X Centromere S51721 FISH, Prader Willi S51722 FISH, Williams S52723 FISH, X-Linked Ichthyosis Steroid Sulfatase Deficiency S51724 FISH, Kallmann S57103 FISH, Chromosome-Specific Probe (please specify chromosome and band) 5836 HER-2/neu [FISH], Breast Cancer Replacement: S51696 FISH, HER-2/neu, Paraffin Block 5866 MALT Lymphoma by FISH Replacement: S51718 FISH, MALT Lymphoma, MALT1, rea18q21 w/reflex to API2/MALT1, t(11;18) 5870 Mantle Cell Lymphoma t(11;14) by FISH Replacement: S51707 FISH, Mantle Cell Lymphoma, IGH/CCND1, t(11;14) 5845 Multiple Myeloma 5 Probes Replacement: S51713 FISH, Myeloma, 13q, 14q, 17p w/reflex to 5,9,15 5864 Multiple Myeloma by FISH Replacement: S51712 FISH, Multiple Myeloma, Chromosomes 5,9,15 5878 Myelodysplastic Syndromes (MDS), Low Grade by FISH Replacement: S51714 FISH, MDS/Myeloid Panel, -5/5q-, -7/7q-, +8,20q 5882 t(12;21) TEL/AML1 by FISH Replacement: S51694 FISH, ALL, TEL/AML1 Translocation 12,21 5886 Trisomy 11 by FISH 5808 Trisomy 8 [FISH] 5838 X & Y Probe Opposite Sex BM Transplant [FISH] Replacement: S51695 FISH, X/Y, Post Opposite Sex Bone Marrow Transplant 4 of 5

Test Changes: Effective November 4, 2008: 1833 ER, PR, Ki-67, p53, HER-2/neu w/reflex FISH, Breast Cancer Component Specimen Source (Add) 1839 ER, PR, Ki-67, HER-2/neu w/reflex FISH, Breast Cancer Component Specimen Source (Add) Component ER Breast Interpretation (Add) Component PR Breast Interpretation (Add) Component HER-2/neu Interpretation (Add) Component Ki-67 Breast Interpretation (Add) 5846 HER-2/neu [IHC] w/reflex FISH, Breast Cancer 1842 ER, PR, HER-2/neu w/reflex FISH, Breast Cancer 1839 ER, PR, Ki-67, HER-2/neu w/reflex FISH, Breast Cancer 1833 ER, PR, Ki-67, p53, HER-2/neu w/reflex FISH, Breast Cancer 1818 ER, PR, DNA CCA, HER-2/neu w/reflex FISH, Breast Cancer HER-2/neu [IHC] will continue to reflex to FISH when result is 2+, for an additional fee. Reflexed panel will be S51696 FISH, HER-2/neu, Paraffin Block 5 of 5